DARPP-32 and t-DARPP promote lung cancer growth through IKKα-dependent cell migration and Akt/Erk-mediated cell survival
S. K. Alam, M. Astone, P. Liu, S. R. Hall, A. M. Coyle, E. N. Dankert, D. K. Hoffman, W. Zhang, R. Kuang, A. C. Roden, A. S. Mansfield, L. H. Hoeppner
Abstract
Lung cancer is the leading cause of cancer-related death worldwide. In this study, we demonstrate that elevated expression of dopamine and cyclic adenosine monophosphate-regulated phosphoprotein, Mr 32000 (DARPP-32) and its truncated splice variant t-DARPP promotes lung tumor growth, while abrogation of DARPP-32 expression in human non-small cell lung cancer (NSCLC) cells reduces tumor growth in orthotopic mouse models. We observe a novel physical interaction between DARPP-32 and inhibitory kappa B kinase- (IKK) that promotes NSCLC cell migration through non-canonical nuclear factor kappa-light-chain-enhancer of activated B cells 2 (NF-{kappa}B2) signaling. Bioinformatics analysis of 513 lung adenocarcinoma patients reveals elevated t-DARPP isoform expression is associated with poor overall survival. Histopathological investigation of 62 human lung adenocarcinoma tissues also showed that t-DARPP expression is elevated with increasing tumor (T) stage. Our data suggest that DARPP-32 is a negative prognostic marker associated with increasing stages of NSCLC and may represent a novel therapeutic target.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- IKKα promotes lung adenocarcinoma growth through activation of ERK signaling via DARPP-32-mediated inhibition of PP1 activity
S. K. Alam, L. Wang, … L. H. Hoeppner·bioRxiv·Jul 8, 2022
- ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumor cell survival
S. K. Alam, L. Wang, … L. H. Hoeppner·bioRxiv·Jul 16, 2019
- DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma
S. K. Alam, Y. Zhang, … L. H. Hoeppner·bioRxiv·Feb 12, 2021
- NKX2-1 controls lung cancer progression by inducing DUSP6 to dampen ERK activity
K. Ingram, S. C. Samson, … M. C. Mendoza·bioRxiv·Mar 4, 2021
- Conditional ERK3 overexpression cooperates with PTEN deletion to promote lung adenocarcinoma formation in mice
S. Vallabhaneni, J. Liu, … W. Long·Molecular OncologyPeer-reviewed·Dec 14, 2021
- RANKL Signaling Sustains Primary Tumor Growth In Genetically Engineered Mouse Models Of Lung Adenocarcinoma